Is Lurbinectedin Safe During Pregnancy?
No, pregnant women should not take lurbinectedin (brand name Zepzelca). It is classified as pregnancy category D by the FDA, meaning there is positive evidence of human fetal risk, but benefits may warrant use in life-threatening situations if alternatives fail.[1] Animal studies show embryo-fetal toxicity, including reduced body weight, skeletal variations, and increased post-implantation loss at doses lower than human equivalents.[2]
What Do Animal Studies and Clinical Data Show?
In rats and rabbits, lurbinectedin caused developmental abnormalities at exposures 0.04 to 0.3 times the human dose. No adequate human pregnancy studies exist due to the drug's oncology use, but its mechanism—DNA damage via trapping topoisomerase I—poses high teratogenic risk.[2][3] Postmarketing reports are limited, but fetal harm is expected.
Official Recommendations for Pregnant Patients
The prescribing information advises:
- Verify pregnancy status before starting.
- Use effective contraception during treatment and for 6 months after (women) or 4 months (men).[2]
- If exposed unintentionally, perform fetal ultrasound and amniocentesis for risk assessment.
- Report exposures to the Zepzelca Pregnancy Exposure Registry (1-888-661-2833).[2]
Alternatives and Risk Management
For small cell lung cancer (SCLC), pregnant patients face trade-offs; chemotherapy is often delayed until after the first trimester or viability. Alternatives like topotecan may carry similar risks (category D).[4] Consult oncology and maternal-fetal medicine specialists. Breastfeeding is not recommended due to excretion in milk.[2]
Legal and Manufacturer Stance
Jazz Pharmaceuticals, Zepzelca's maker, mandates a Risk Evaluation and Mitigation Strategy (REMS) emphasizing fetal risks, with black-box warnings.[2] Liability concerns arise from off-label use in pregnancy.
[1] FDA Label for Zepzelca (lurbinectedin), Section 8.1. FDA.gov
[2] Zepzelca Prescribing Information, Sections 5.5 and 8. ZepzelcaHCP.com
[3] Lurbinectedin pharmacology review, EMA assessment. EMA.europa.eu
[4] NCCN Guidelines for SCLC, pregnancy considerations (v2.2023). NCCN.org